Drs Rosenblat and McIntyre Reply
Clicks: 83
ID: 118185
2020
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
24.3
/100
83 views
19 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #231 of 273 articles by views in the journal of clinical psychiatry
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 273 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Rosenblat and McIntyre reply to the letter “Sublingual Ketamine: An Option for Increasing Accessibility of Ketamine Treatments for Depression?” by Swainson and Khullar.
| Reference Key |
rosenblat2020the
drs
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Joshua D. Rosenblat;Roger S. McIntyre; |
| Journal | the journal of clinical psychiatry |
| Year | 2020 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.